期刊
EXPERIMENTAL NEUROLOGY
卷 224, 期 1, 页码 66-73出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2010.03.024
关键词
-
资金
- CIBERNED [CB06/05/1109]
- Ministerio de Ciencia e Innovacion Tecnologica [SAF 2007/61565]
- Fondo de Investigaciones Sanitarias (FIS) [PS09/01900]
- Comunidad de Madrid [S-SAL/0261/2006]
- Spanish Ministry of Science (MICINN)
The endocannabinoid system may be the target of novel therapies in a wide variety of diseases. Among them, those related with amyloid accumulation will be discussed in the present review. Several components of this system (CB1 and CB2 receptors, endocannabinoids, FAAH enzyme) may participate in different aspects of amyloid pathophysiology such as, for instance, synaptic activity, cell migration, cytokine production or phagocytic activity. Consistent with recent data, putative lines of research and hypothesis will be discussed. (C) 2010 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据